Trubion Announces Dates for Third Quarter and Nine Months 2009 Earnings Conference Call

Trubion Announces Dates for Third Quarter and Nine Months 2009 Earnings
Conference Call

SEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc.
(Nasdaq: TRBN), today announced that it plans to issue earnings results for
its third quarter and nine months ended Sept. 30, 2009, after the close of
market on Nov. 5, 2009. The company's earnings conference call will take place
Nov. 5, 2009 at 2 p.m. Pacific Time, 5 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

The live event will be available for viewing on Trubion's website at
http://investors.trubion.com.

Third Quarter and Nine Months 2009 Earnings Conference Call: 2 p.m. PST / 5
p.m. EST, Nov. 5, 2009

Trubion will host a conference call and webcast to discuss its third quarter
and nine months ended Sept. 30, 2009 financial results and provide an update
on business activities. The call will be held Nov. 5 at 2 p.m. Pacific Time, 5
p.m. Eastern Time. The live event will be available from Trubion's website at
http://investors.trubion.com, or by calling (703) 639-1156 or (866) 238-0637.
A replay of the discussion will be available beginning at 8 p.m. Eastern Time
from Trubion's website or by calling (703) 925-2533 or (888) 266-2081 and
entering 1408250. The telephone replay will be available until midnight, Nov.
11, 2009.

About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of novel
protein therapeutic product candidates to treat autoimmune and inflammatory
diseases and cancer. The Company's mission is to develop a variety of
first-in-class and best-in-class product candidates, customized for optimal
safety, efficacy and convenience that it believes may offer improved patient
experiences. Trubion's current product candidates are novel single-chain
protein, or SMIP, therapeutics, and are designed using its custom drug
assembly technology. Trubion's product pipeline includes CD20-directed SMIP
therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory
diseases, developed under the Company's Pfizer collaboration. Trubion's
product pipeline also includes TRU-016, a novel CD37-targeted therapy for the
treatment of B-cell malignancies developed under the company's Facet Biotech
collaboration. In addition to Trubion's current clinical stage product
pipeline, the Company is also developing its multi-specific SCORPION
technology, both for targeting cell-surface molecules like CD79b and HLA-DR,
as well simultaneously neutralizing soluble ligands like TNF and IL-6. More
information is available in the investors section of Trubion's website:
http://investors.trubion.com/index.cfm

TRBN-G

Contact:
Jim DeNike
Senior Director, Corporate Communications
Trubion Pharmaceuticals Inc.
(206) 838-0500

Waggener Edstrom Worldwide Healthcare
Amy Petty
Senior Account Executive
(617) 576-5788

SOURCE Trubion Pharmaceuticals, Inc.

Jim DeNike Senior Director, Corporate Communications of Trubion
Pharmaceuticals Inc., +1-206-838-0500, jdenike@trubion.com; or Amy Petty,
Senior Account Executive of Waggener Edstrom Worldwide Healthcare,
+1-617-576-5788, amyp@waggeneredstrom.com for Trubion Pharmaceuticals Inc.